Hyperexcitability of peripheral nociceptive pathways is often associated with
inflammation and is an important mechanism underlying inflammatory
pain. Here we describe a completely novel mechanism via which nociceptor
G-protein-coupled receptor kinase 2 (GRK2) contributes to regulation of inflammatory
hyperalgesia. We show that nociceptor GRK2 is downregulated during
inflammation. In addition, we show for the first time that
prostaglandin E2 (PGE2)-induced
hyperalgesia is prolonged from <6 h in wild-type (WT) mice to 3 d in mice with low GRK2 in Nav1.8+ nociceptors (SNS-GRK2+/- mice). This prolongation of
PGE2 hyperalgesia in SNS-GRK2+/- mice does not depend on changes in the sensitivity of the
prostaglandin receptors because prolonged
hyperalgesia also developed in response to 8-Br-cAMP.
PGE2 or cAMP-induced
hyperalgesia in WT mice is PKA dependent. However, PKA activity is not required for
hyperalgesia in SNS-GRK2+/- mice. SNS-GRK2+/- mice developed prolonged
hyperalgesia in response to the Exchange
proteins directly activated by cAMP (
Epac) activator
8-pCPT-2'-O-Me-cAMP (8-pCPT). Coimmunoprecipitation experiments showed that GRK2 binds to Epac1. In vitro, GRK2 deficiency increased 8-pCPT-induced activation of the downstream effector of
Epac, Rap1, and
extracellular signal-regulated kinase (ERK). In vivo, inhibition of MEK1 or PKCĪµ prevented prolonged
PGE2, 8-Br-cAMP, and 8-pCPT
hyperalgesia in SNS-GRK2+/- mice. In conclusion, we discovered GRK2 as a novel Epac1-interacting
protein. A reduction in the cellular level of GRK2 enhances activation of the Epac-Rap1 pathway. In vivo, low nociceptor GRK2 leads to prolonged inflammatory
hyperalgesia via biased cAMP signaling from PKA to Epac-Rap1, ERK/PKCĪµ pathways.